Can I read Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort on EtoBox?

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort by Stefanie Zschäbitz; Nadine Biernath; Thomas Hilser; Alexander Höllein; Friedemann Zengerling; Jozefina Cascucelli; Pia Paffenholz; Daniel Seidl; Christoph Lutz; Katrin Schlack; Dorothea Kingreen; Niklas Klümper; Philipp Ivanyi; Gunhild von Amsberg; Hendrik Heers; Florian Roghmann; Robert L. Tauber; Richard Cathomas; Luisa Hofer; Günter Niegisch; Melanie Klee; Roland Ehrenberg; Andreas Hassler; Boris A. Hadaschik; Viktor Grünwald; Christopher Darr is a Medicine article available to read on EtoBox.

What is Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort about?

## Take Home Message Administration of enfortumab vedotin in real-world patients was feasible with an acceptable toxicity profile. Antitumor activity in our cohort was comparable to data previously reported from trials. In summary, our results support the use of enfortumab vedotin in real-world patients with metastatic urothelial carcinoma.

Who reads Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort?

Author

Stefanie Zschäbitz; Nadine Biernath; Thomas Hilser; Alexander Höllein; Friedemann Zengerling; Jozefina Cascucelli; Pia Paffenholz; Daniel Seidl; Christoph Lutz; Katrin Schlack; Dorothea Kingreen; Niklas Klümper; Philipp Ivanyi; Gunhild von Amsberg; Hendrik Heers; Florian Roghmann; Robert L. Tauber; Richard Cathomas; Luisa Hofer; Günter Niegisch; Melanie Klee; Roland Ehrenberg; Andreas Hassler; Boris A. Hadaschik; Viktor Grünwald; Christopher Darr

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)